Lanying Du

InstitutionLindsley F. Kimball Research Institute
AddressNew York
New York
United States
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 23 Covid-19 publications, with a maximum of 4 publications in May 2020
    All Publications
    Bar chart showing 130 publications over 17 distinct years, with a maximum of 20 publications in 2020
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Ye G, Gallant J, Zheng J, Massey C, Shi K, Tai W, Odle A, Vickers M, Shang J, Wan Y, Du L, Aihara H, Perlman S, LeBeau A, Li F. The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates. Elife. 2021 08 02; 10. PMID: 34338634.
      Citations:    Fields:    Translation:HumansAnimalsCellsPHPublic Health
    2. Yang Y, Du L. SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies. Signal Transduct Target Ther. 2021 02 26; 6(1):95. PMID: 33637679.
    3. Cao W, Dong C, Kim S, Hou D, Tai W, Du L, Im W, Zhang XF. Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2 protein-protein interaction. Biophys J. 2021 03 16; 120(6):1011-1019. PMID: 33607086.
      Citations: 5     Fields:    Translation:HumansCells
    4. Jiang S, Zhang X, Yang Y, Hotez PJ, Du L. Neutralizing antibodies for the treatment of COVID-19. Nat Biomed Eng. 2020 12; 4(12):1134-1139. PMID: 33293725.
      Citations: 23     Fields:    Translation:HumansPHPublic Health
    5. Su S, Du L, Jiang S. Learning from the past: development of safe and effective COVID-19 vaccines. Nat Rev Microbiol. 2021 03; 19(3):211-219. PMID: 33067570.
      Citations: 27     Fields:    Translation:Humans
    6. Chen WH, Tao X, Agrawal AS, Algaissi A, Peng BH, Pollet J, Strych U, Bottazzi ME, Hotez PJ, Lustigman S, Du L, Jiang S, Tseng CK. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement. Vaccine. 2020 11 03; 38(47):7533-7541. PMID: 33039209.
      Citations: 20     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    7. Jiang S, Zhang X, Du L. Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2. Expert Opin Ther Targets. 2021 06; 25(6):415-421. PMID: 32941780.
      Citations: 7     Fields:    Translation:Humans
    8. Zhang N, Shang J, Li C, Zhou K, Du L. An overview of Middle East respiratory syndrome coronavirus vaccines in preclinical studies. Expert Rev Vaccines. 2020 09; 19(9):817-829. PMID: 32842811.
      Citations: 1     Fields:    Translation:HumansCells
    9. Jiang S, Du L. Effect of Low-Pathogenic Human Coronavirus-Specific Antibodies on SARS-CoV-2. Trends Immunol. 2020 10; 41(10):853-854. PMID: 32863133.
      Citations: 2     Fields:    Translation:HumansCellsPHPublic Health
    10. Tai W, Zhang X, Drelich A, Shi J, Hsu JC, Luchsinger L, Hillyer CD, Tseng CK, Jiang S, Du L. A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2. Cell Res. 2020 10; 30(10):932-935. PMID: 32759966.
      Citations: 27     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    11. George PJ, Tai W, Du L, Lustigman S. The Potency of an Anti-MERS Coronavirus Subunit Vaccine Depends on a Unique Combinatorial Adjuvant Formulation. Vaccines (Basel). 2020 May 27; 8(2). PMID: 32471056.
    12. Tai W, Zhang X, He Y, Jiang S, Du L. Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2. Antiviral Res. 2020 07; 179:104820. PMID: 32405117.
      Citations: 31     Fields:    Translation:HumansCellsPHPublic Health
    13. Ma C, Su S, Wang J, Wei L, Du L, Jiang S. From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development. Microbes Infect. 2020 Jul - Aug; 22(6-7):245-253. PMID: 32437926.
      Citations: 14     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    14. Zhang N, Li C, Hu Y, Li K, Liang J, Wang L, Du L, Jiang S. Current development of COVID-19 diagnostics, vaccines and therapeutics. Microbes Infect. 2020 Jul - Aug; 22(6-7):231-235. PMID: 32387332.
      Citations: 15     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    15. Jiang S, Hillyer C, Du L. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses: (Trends in Immunology 41, 355-359; 2020). Trends Immunol. 2020 06; 41(6):545. PMID: 32362491.
      Citations: 40     Fields:    
    16. Jiang S, Hillyer C, Du L. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses. Trends Immunol. 2020 05; 41(5):355-359. PMID: 32249063.
      Citations: 246     Fields:    Translation:HumansCellsPHPublic Health
    17. Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020 Apr; 30(4):343-355. PMID: 32231345.
      Citations: 349     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    18. Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, Zhou Y, Du L. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020 06; 17(6):613-620. PMID: 32203189.
      Citations: 416     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    19. Wang N, Shang J, Jiang S, Du L. Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses. Front Microbiol. 2020; 11:298. PMID: 32265848.
    20. Wan Y, Shang J, Sun S, Tai W, Chen J, Geng Q, He L, Chen Y, Wu J, Shi Z, Zhou Y, Du L, Li F. Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry. J Virol. 2020 02 14; 94(5). PMID: 31826992.
      Citations: 228     Fields:    Translation:HumansCells
    21. Zhang N, Wang L, Deng X, Liang R, Su M, He C, Hu L, Su Y, Ren J, Yu F, Du L, Jiang S. Recent advances in the detection of respiratory virus infection in humans. J Med Virol. 2020 04; 92(4):408-417. PMID: 31944312.
      Citations: 102     Fields:    Translation:HumansCells
    22. Yu F, Du L, Ojcius DM, Pan C, Jiang S. Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes Infect. 2020 03; 22(2):74-79. PMID: 32017984.
      Citations: 118     Fields:    Translation:HumansCells
    23. Jiang S, Du L, Shi Z. An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies. Emerg Microbes Infect. 2020; 9(1):275-277. PMID: 32005086.
      Citations: 90     Fields:    Translation:HumansAnimalsCells
    24. Li F, Du L. MERS Coronavirus: An Emerging Zoonotic Virus. Viruses. 2019 07 19; 11(7). PMID: 31331035.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    25. Xia S, Yan L, Xu W, Agrawal AS, Algaissi A, Tseng CK, Wang Q, Du L, Tan W, Wilson IA, Jiang S, Yang B, Lu L. A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci Adv. 2019 04; 5(4):eaav4580. PMID: 30989115.
      Citations: 134     Fields:    Translation:HumansAnimalsCells
    26. He L, Tai W, Li J, Chen Y, Gao Y, Li J, Sun S, Zhou Y, Du L, Zhao G. Enhanced Ability of Oligomeric Nanobodies Targeting MERS Coronavirus Receptor-Binding Domain. Viruses. 2019 02 19; 11(2). PMID: 30791410.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    27. Zhou Y, Yang Y, Huang J, Jiang S, Du L. Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain. Viruses. 2019 01 14; 11(1). PMID: 30646569.
      Citations: 36     Fields:    Translation:HumansAnimalsCells
    28. Zhao G, He L, Sun S, Qiu H, Tai W, Chen J, Li J, Chen Y, Guo Y, Wang Y, Shang J, Ji K, Fan R, Du E, Jiang S, Li F, Du L, Zhou Y. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV. J Virol. 2018 09 15; 92(18). PMID: 29950421.
      Citations: 30     Fields:    Translation:HumansAnimalsCells
    29. Zhou Y, Jiang S, Du L. Prospects for a MERS-CoV spike vaccine. Expert Rev Vaccines. 2018 08; 17(8):677-686. PMID: 30058403.
      Citations: 44     Fields:    Translation:HumansAnimalsCells
    30. Jiang Y, Zhao G, Song N, Li P, Chen Y, Guo Y, Li J, Du L, Jiang S, Guo R, Sun S, Zhou Y. Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV. Emerg Microbes Infect. 2018 Apr 24; 7(1):77. PMID: 29691378.
      Citations: 83     Fields:    Translation:HumansAnimalsCells
    31. Nyon MP, Du L, Tseng CK, Seid CA, Pollet J, Naceanceno KS, Agrawal A, Algaissi A, Peng BH, Tai W, Jiang S, Bottazzi ME, Strych U, Hotez PJ. Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen. Vaccine. 2018 03 27; 36(14):1853-1862. PMID: 29496347.
      Citations: 26     Fields:    Translation:AnimalsCells
    32. Shang J, Zheng Y, Yang Y, Liu C, Geng Q, Tai W, Du L, Zhou Y, Zhang W, Li F. Cryo-Electron Microscopy Structure of Porcine Deltacoronavirus Spike Protein in the Prefusion State J Virol. 2018 02 15; 92(4). PMID: 29070693.
      Citations: 37     Fields:    Translation:HumansAnimalsCells
    33. Zeng LP, Ge XY, Peng C, Tai W, Jiang S, Du L, Shi ZL. Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses. Sci China Life Sci. 2017 12; 60(12):1399-1402. PMID: 29134417.
      Citations: 14     Fields:    Translation:AnimalsCells
    34. Wang Y, Tai W, Yang J, Zhao G, Sun S, Tseng CK, Jiang S, Zhou Y, Du L, Gao J. Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection. Hum Vaccin Immunother. 2017 07 03; 13(7):1615-1624. PMID: 28277821.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    35. Du L, Yang Y, Zhou Y, Lu L, Li F, Jiang S. MERS-CoV spike protein: a key target for antivirals. Expert Opin Ther Targets. 2017 Feb; 21(2):131-143. PMID: 27936982.
      Citations: 90     Fields:    Translation:HumansAnimalsCells
    36. Tai W, Wang Y, Fett CA, Zhao G, Li F, Perlman S, Jiang S, Zhou Y, Du L. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants. J Virol. 2017 Jan 01; 91(1). PMID: 27795425.
      Citations: 36     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    37. Du L, Tai W, Yang Y, Zhao G, Zhu Q, Sun S, Liu C, Tao X, Tseng CK, Perlman S, Jiang S, Zhou Y, Li F. Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines. Nat Commun. 2016 11 22; 7:13473. PMID: 27874853.
      Citations: 51     Fields:    Translation:HumansAnimalsCells
    38. Tai W, Zhao G, Zhao G, Sun S, Guo Y, Guo Y, Wang Y, Wang Y, Tao X, Tseng CK, Li F, Li F, Jiang S, Du L, Zhou Y. A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection. Virology. 2016 12; 499:375-382. PMID: 27750111.
      Citations: 43     Fields:    Translation:HumansAnimalsCells
    39. Liu C, Liu C, Ma Y, Yang Y, Yang Y, Zheng Y, Zheng Y, Shang J, Zhou Y, Jiang S, Du L, Li J, Li F. Cell Entry of Porcine Epidemic Diarrhea Coronavirus Is Activated by Lysosomal Proteases. J Biol Chem. 2016 Nov 18; 291(47):24779-24786. PMID: 27729455.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    40. Qiu H, Sun S, Xiao H, Feng J, Guo Y, Tai W, Wang Y, Du L, Zhao G, Zhou Y. Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection. Antiviral Res. 2016 08; 132:141-8. PMID: 27312105.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    41. Du L, Tai W, Zhou Y, Jiang S. Vaccines for the prevention against the threat of MERS-CoV. Expert Rev Vaccines. 2016 09; 15(9):1123-34. PMID: 26985862.
      Citations: 35     Fields:    Translation:HumansAnimalsCells
    42. Zhao G, Jiang Y, Qiu H, Gao T, Zeng Y, Guo Y, Yu H, Li J, Kou Z, Du L, Tan W, Jiang S, Sun S, Zhou Y. Multi-Organ Damage in Human Dipeptidyl Peptidase 4 Transgenic Mice Infected with Middle East Respiratory Syndrome-Coronavirus. PLoS One. 2015; 10(12):e0145561. PMID: 26701103.
      Citations: 42     Fields:    Translation:HumansAnimalsCells
    43. Tao X, Garron T, Agrawal AS, Algaissi A, Peng BH, Wakamiya M, Chan TS, Lu L, Du L, Jiang S, Couch RB, Tseng CT. Characterization and Demonstration of the Value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease. J Virol. 2016 01 01; 90(1):57-67. PMID: 26446606.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    44. Du L, Jiang S. Middle East respiratory syndrome: current status and future prospects for vaccine development. Expert Opin Biol Ther. 2015; 15(11):1647-51. PMID: 26414077.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    45. Ying T, Prabakaran P, Du L, Shi W, Feng Y, Wang Y, Wang L, Li W, Jiang S, Dimitrov DS, Zhou T. Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody. Nat Commun. 2015 Sep 15; 6:8223. PMID: 26370782.
      Citations: 58     Fields:    Translation:HumansCells
    46. Yang Y, Liu C, Du L, Jiang S, Shi Z, Baric RS, Li F. Two Mutations Were Critical for Bat-to-Human Transmission of Middle East Respiratory Syndrome Coronavirus. J Virol. 2015 Sep; 89(17):9119-23. PMID: 26063432.
      Citations: 54     Fields:    Translation:HumansAnimalsCells
    47. Channappanavar R, Lu L, Xia S, Du L, Meyerholz DK, Perlman S, Jiang S. Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection. J Infect Dis. 2015 Dec 15; 212(12):1894-903. PMID: 26164863.
      Citations: 44     Fields:    Translation:HumansAnimalsCells
    48. Liu C, Tang J, Ma Y, Liang X, Yang Y, Peng G, Qi Q, Jiang S, Li J, Du L, Li F. Receptor usage and cell entry of porcine epidemic diarrhea coronavirus. J Virol. 2015 Jun; 89(11):6121-5. PMID: 25787280.
      Citations: 72     Fields:    Translation:HumansAnimalsCells
    49. Zhang N, Channappanavar R, Ma C, Wang L, Tang J, Garron T, Tao X, Tasneem S, Lu L, Tseng CT, Zhou Y, Perlman S, Jiang S, Du L. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. Cell Mol Immunol. 2016 Mar; 13(2):180-90. PMID: 25640653.
      Citations: 56     Fields:    Translation:HumansAnimalsCells
    50. Tang J, Zhang N, Tao X, Zhao G, Guo Y, Tseng CT, Jiang S, Du L, Zhou Y. Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus. Hum Vaccin Immunother. 2015; 11(5):1244-50. PMID: 25874632.
      Citations: 40     Fields:    Translation:HumansAnimalsCells
    51. Zhang N, Tang J, Lu L, Jiang S, Du L. Receptor-binding domain-based subunit vaccines against MERS-CoV. Virus Res. 2015 Apr 16; 202:151-9. PMID: 25445336.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    52. Liu Q, Xia S, Sun Z, Wang Q, Du L, Lu L, Jiang S. Testing of Middle East respiratory syndrome coronavirus replication inhibitors for the ability to block viral entry. Antimicrob Agents Chemother. 2015 Jan; 59(1):742-4. PMID: 25331705.
      Citations: 21     Fields:    Translation:HumansCells
    53. Xia S, Liu Q, Liu Q, Wang Q, Wang Q, Sun Z, Su S, Du L, Ying T, Lu L, Lu L, Jiang S. Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. Virus Res. 2014 Dec 19; 194:200-10. PMID: 25451066.
      Citations: 47     Fields:    Translation:HumansCells
    54. Ma C, Wang L, Tao X, Zhang N, Yang Y, Tseng CK, Li F, Zhou Y, Jiang S, Du L. Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments--the importance of immunofocusing in subunit vaccine design. Vaccine. 2014 Oct 21; 32(46):6170-6176. PMID: 25240756.
      Citations: 65     Fields:    Translation:HumansAnimalsCells
    55. Yang Y, Du L, Liu C, Wang L, Ma C, Tang J, Baric RS, Jiang S, Li F. Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus. Proc Natl Acad Sci U S A. 2014 Aug 26; 111(34):12516-21. PMID: 25114257.
      Citations: 105     Fields:    Translation:HumansAnimalsCells
    56. Hotez PJ, Bottazzi ME, Tseng CT, Zhan B, Lustigman S, Du L, Jiang S. Calling for rapid development of a safe and effective MERS vaccine. Microbes Infect. 2014 Jul; 16(7):529-31. PMID: 24931059.
      Citations: 17     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    57. Ying T, Du L, Ju TW, Prabakaran P, Lau CC, Lu L, Liu Q, Wang L, Feng Y, Wang Y, Zheng BJ, Yuen KY, Jiang S, Dimitrov DS. Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J Virol. 2014 Jul; 88(14):7796-805. PMID: 24789777.
      Citations: 104     Fields:    Translation:HumansCells
    58. Zhang N, Jiang S, Du L. Current advancements and potential strategies in the development of MERS-CoV vaccines. Expert Rev Vaccines. 2014 Jun; 13(6):761-74. PMID: 24766432.
      Citations: 67     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    59. Du L, Zhao G, Yang Y, Qiu H, Wang L, Kou Z, Tao X, Yu H, Sun S, Tseng CT, Jiang S, Li F, Zhou Y. A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. J Virol. 2014 Jun; 88(12):7045-53. PMID: 24719424.
      Citations: 66     Fields:    Translation:HumansAnimalsCells
    60. Ma C, Li Y, Wang L, Zhao G, Tao X, Tseng CT, Zhou Y, Du L, Jiang S. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. Vaccine. 2014 Apr 11; 32(18):2100-8. PMID: 24560617.
      Citations: 66     Fields:    Translation:HumansAnimalsCells
    61. Lu L, Liu Q, Zhu Y, Chan KH, Qin L, Li Y, Wang Q, Chan JF, Du L, Yu F, Ma C, Ye S, Yuen KY, Zhang R, Jiang S. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun. 2014; 5:3067. PMID: 24473083.
      Citations: 148     Fields:    Translation:HumansCells
    62. Chen WH, Du L, Chag SM, Ma C, Tricoche N, Tao X, Seid CA, Hudspeth EM, Lustigman S, Tseng CT, Bottazzi ME, Hotez PJ, Zhan B, Jiang S. Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate. Hum Vaccin Immunother. 2014; 10(3):648-58. PMID: 24355931.
      Citations: 45     Fields:    Translation:AnimalsCells
    63. Du L, Kou Z, Ma C, Tao X, Wang L, Zhao G, Chen Y, Yu F, Tseng CT, Zhou Y, Jiang S. A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS One. 2013; 8(12):e81587. PMID: 24324708.
      Citations: 83     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    64. Zhao G, Du L, Ma C, Li Y, Li L, Poon VK, Wang L, Yu F, Zheng BJ, Jiang S, Zhou Y. A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV. Virol J. 2013 Aug 26; 10:266. PMID: 23978242.
      Citations: 51     Fields:    Translation:HumansAnimalsCells
    65. Zhu X, Liu Q, Liu Q, Du L, Lu L, Lu L, Jiang S. Receptor-binding domain as a target for developing SARS vaccines. J Thorac Dis. 2013 Aug; 5 Suppl 2:S142-8. PMID: 23977435.
    66. Du L, Zhao G, Kou Z, Ma C, Sun S, Poon VK, Lu L, Wang L, Debnath AK, Zheng BJ, Zhou Y, Jiang S. Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J Virol. 2013 Sep; 87(17):9939-42. PMID: 23824801.
      Citations: 84     Fields:    Translation:HumansAnimalsCells
    67. Lu L, Liu Q, Du L, Jiang S. Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread. Microbes Infect. 2013 Jul-Aug; 15(8-9):625-9. PMID: 23791956.
      Citations: 36     Fields:    Translation:HumansCellsPHPublic Health
    68. Du L, Ma C, Jiang S. Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC. J Infect. 2013 Oct; 67(4):348-50. PMID: 23685240.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    69. Jiang S, Lu L, Du L, Debnath AK. Putative conformations of the receptor-binding domain in S protein of hCoV-EMC in complex with its receptor dipeptidyl peptidase-4. J Infect. 2013 Aug; 67(2):156-8. PMID: 23603488.
      Citations: 4     Fields:    Translation:HumansCells
    70. Jiang S, Lu L, Du L, Debnath AK. A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC. J Infect. 2013 May; 66(5):464-6. PMID: 23266463.
      Citations: 25     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    71. Jiang S, Bottazzi ME, Du L, Lustigman S, Tseng CT, Curti E, Jones K, Zhan B, Hotez PJ. Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. Expert Rev Vaccines. 2012 Dec; 11(12):1405-13. PMID: 23252385.
      Citations: 53     Fields:    Translation:HumansAnimalsCells
    72. Jiang S, Lu L, Liu Q, Xu W, Du L. Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines. Emerg Microbes Infect. 2012 Aug; 1(8):e13. PMID: 26038424.
      Citations: 18     Fields:    
    73. Wang J, Tricoche N, Du L, Hunter M, Zhan B, Goud G, Didier ES, Liu J, Lu L, Marx PA, Jiang S, Lustigman S. The adjuvanticity of an O. volvulus-derived rOv-ASP-1 protein in mice using sequential vaccinations and in non-human primates. PLoS One. 2012; 7(5):e37019. PMID: 22615877.
      Citations: 17     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    74. Du L, Zhang X, Liu J, Jiang S. Protocol for recombinant RBD-based SARS vaccines: protein preparation, animal vaccination and neutralization detection. J Vis Exp. 2011 May 02; (51). PMID: 21587153.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    75. Cao Z, Liu L, Du L, Zhang C, Jiang S, Li T, He Y. Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients. Virol J. 2010 Nov 04; 7:299. PMID: 21047436.
      Citations: 35     Fields:    Translation:HumansAnimalsCells
    76. Du L, Zhao G, Chan CC, Li L, He Y, Zhou Y, Zheng BJ, Jiang S. A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity. Viral Immunol. 2010 Apr; 23(2):211-9. PMID: 20374001.
      Citations: 23     Fields:    Translation:AnimalsCells
    77. Du L, Zhao G, Chan CC, Sun S, Chen M, Liu Z, Guo H, He Y, Zhou Y, Zheng BJ, Jiang S. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology. 2009 Oct 10; 393(1):144-50. PMID: 19683779.
      Citations: 52     Fields:    Translation:AnimalsCells
    78. Du L, Zhao G, Li L, He Y, Zhou Y, Zheng BJ, Jiang S. Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells. Biochem Biophys Res Commun. 2009 Jul 10; 384(4):486-90. PMID: 19422787.
      Citations: 24     Fields:    Translation:AnimalsCellsPHPublic Health
    79. Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009 Mar; 7(3):226-36. PMID: 19198616.
      Citations: 520     Fields:    Translation:HumansAnimalsCells
    80. Du L, Zhao G, Lin Y, Chan C, He Y, Jiang S, Wu C, Jin DY, Yuen KY, Zhou Y, Zheng BJ. Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection. Vaccine. 2008 Mar 20; 26(13):1644-51. PMID: 18289745.
      Citations: 40     Fields:    Translation:AnimalsCells
    81. Du L, Zhao G, Lin Y, Sui H, Chan C, Ma S, He Y, Jiang S, Wu C, Yuen KY, Jin DY, Zhou Y, Zheng BJ. Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection. J Immunol. 2008 Jan 15; 180(2):948-56. PMID: 18178835.
      Citations: 60     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    82. Du L, He Y, Jiang S, Zheng BJ. Development of subunit vaccines against severe acute respiratory syndrome. Drugs Today (Barc). 2008 Jan; 44(1):63-73. PMID: 18301805.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    83. Du L, Kao RY, Zhou Y, He Y, Zhao G, Wong C, Jiang S, Yuen KY, Jin DY, Zheng BJ. Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity. Biochem Biophys Res Commun. 2007 Jul 20; 359(1):174-9. PMID: 17533109.
      Citations: 48     Fields:    Translation:HumansCells
    84. Du L, Zhao G, He Y, Guo Y, Zheng BJ, Jiang S, Zhou Y. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine. 2007 Apr 12; 25(15):2832-8. PMID: 17092615.
      Citations: 78     Fields:    Translation:AnimalsCells
    85. Lu W, Zheng BJ, Xu K, Schwarz W, Du L, Wong CK, Chen J, Duan S, Deubel V, Sun B. Severe acute respiratory syndrome-associated coronavirus 3a protein forms an ion channel and modulates virus release. Proc Natl Acad Sci U S A. 2006 Aug 15; 103(33):12540-5. PMID: 16894145.
      Citations: 92     Fields:    Translation:HumansAnimalsCells
    86. Du L, He Y, Wang Y, Zhang H, Ma S, Wong CK, Wu SH, Ng F, Huang JD, Yuen KY, Jiang S, Zhou Y, Zheng BJ. Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines. Virology. 2006 Sep 15; 353(1):6-16. PMID: 16793110.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    87. He Y, Li J, Du L, Yan X, Hu G, Zhou Y, Jiang S. Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine. Vaccine. 2006 Jun 29; 24(26):5498-508. PMID: 16725238.
      Citations: 27     Fields:    Translation:AnimalsCells
    88. Zheng BJ, Guan Y, Hez ML, Sun H, Du L, Zheng Y, Wong KL, Chen H, Chen Y, Lu L, Tanner JA, Watt RM, Niccolai N, Bernini A, Spiga O, Woo PC, Kung HF, Yuen KY, Huang JD. Synthetic peptides outside the spike protein heptad repeat regions as potent inhibitors of SARS-associated coronavirus. Antivir Ther. 2005; 10(3):393-403. PMID: 15918330.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    Du's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (385)
    Co-Authors (368)
    Similar People (60)
    Physical Neighbors